Back

Aldosterone suppression is more effective than blood pressure reduction in reversing cardiac remodelling due to primary aldosteronism: the MATCH and PATHWAY-1 prospective CMR sub-studies

30 August 2026 (14:15 - 14:30)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition Renin-Angiotensin System ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor James Morris Wilson

Barts Heart Centre, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Effects of finerenone in patients with hypertensive nephropathy
Professor H. Heerspink (Groningen, NL)
Slides Video
Presentation thumbnail
Extended Follow-Up of the KARDINAL Trial Assessing the Effect of Tonlamarsen in Uncontrolled Hypertension
Associate Professor L. Laffin (Cleveland, US)
Slides Video
Presentation thumbnail
Long-term efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension: results from the BaxHTN phase 3 trial
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Efficacy and safety of finerenone in patients with chronic kidney disease and cardiovascular diseases: An individual participant data pooled analysis (INFINITY)
Professor C. Lam (Singapore, SG)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Clinical Science: renin-angiotensin-aldosterone pathway inhibition
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Autonomous cortisol secretion in patients with primary aldosteronism is associated with left ventricular hypertrophy and diastolic dysfunction
1 September 2024
thumbnail
Congress Presentation
Aldosterone-targeted therapies in hypertension
30 August 2025
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling
1 September 2024
thumbnail
Congress Session
The hypertensive heart: from hypertrophy to failure
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources